Li Huakang, Huang Wei, Du Kangming, Liu Wei, Wu Ziliang, Xu Bo, Li Qiang, Wang Yue, Lin Bing
Department of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Department of Vascular Surgery, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Front Oncol. 2023 Jun 8;13:1199200. doi: 10.3389/fonc.2023.1199200. eCollection 2023.
This study aimed to investigate the efficacy and mechanism of action of Governor Vessel Moxibustion (GVM) in the treatment of Cancer-Related Fatigue (CRF) in patients who have completed treatment for colorectal cancer.
We randomly assigned 80 CRF patients in a 1:1 ratio to either the experimental group or the control group. During the three-week treatment period, both groups of patients received usual care for CRF provided by professional nurses. The experimental group received additional GVM treatment (three times a week, nine times total). The primary outcome was the mean change in total fatigue score from baseline to the end of treatment, assessed using the Chinese version of the Piper Fatigue Scale.
At baseline, the total fatigue scores were 6.20 ± 0.12 in the experimental group and 6.16 ± 0.14 in the control group. At the end of treatment, the total fatigue scores decreased by 2.03 points (32.7% decrease from baseline) in the experimental group and by 0.99 points (15.6% decrease from baseline) in the control group. The absolute reduction in total fatigue scores in the experimental group was 1.04 points higher than in the control group (95% CI, 0.93 to 1.15; <0.001), corresponding to a relative difference of 17.1% (95% CI, 15.2% to 18.9%; <0.001). At the end of treatment, the experimental group showed greater reductions in interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels compared to the control group. No serious adverse events related to GVM treatment were observed.
GVM appears to be safe and effective for alleviating CRF in patients who have completed colorectal cancer treatment, which may be related to the modulation of IL-6 and TNF-α levels.
Chinese Clinical Trials Registry: ChiCTR2300069208.
本研究旨在探讨督脉灸治疗已完成结直肠癌治疗患者的癌因性疲乏（CRF）的疗效及作用机制。
我们将80例CRF患者按1:1比例随机分为实验组和对照组。在为期三周的治疗期间，两组患者均接受专业护士提供的CRF常规护理。实验组额外接受督脉灸治疗（每周三次，共九次）。主要结局是从基线到治疗结束时总疲乏评分的平均变化，采用中文版Piper疲乏量表进行评估。
基线时，实验组总疲乏评分为6.20±0.12，对照组为6.16±0.14。治疗结束时，实验组总疲乏评分下降了2.03分（较基线下降32.7%），对照组下降了0.99分（较基线下降15.6%）。实验组总疲乏评分的绝对降低值比对照组高1.04分（95%CI，0.93至1.15；<0.001），相对差异为17.1%（95%CI，15.2%至18.9%；<0.001）。治疗结束时，与对照组相比，实验组白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平下降幅度更大。未观察到与督脉灸治疗相关的严重不良事件。
督脉灸似乎对缓解已完成结直肠癌治疗患者的CRF安全有效，这可能与调节IL-6和TNF-α水平有关。
中国临床试验注册中心：ChiCTR2300069208。
